BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

4399 related articles for article (PubMed ID: 6349844)

  • 1. Blood clearance of radioactively labelled cis-diammine 1,1-cyclobutane dicarboxylate platinum (II) (CBDCA) in cancer patients.
    Sharma H; Thatcher N; Baer J; Zaki A; Smith A; McAucliffe CA; Crowther D; Owens S; Fox BW
    Cancer Chemother Pharmacol; 1983; 11(1):5-7. PubMed ID: 6349844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function.
    Harland SJ; Newell DR; Siddik ZH; Chadwick R; Calvert AH; Harrap KR
    Cancer Res; 1984 Apr; 44(4):1693-7. PubMed ID: 6367971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum II (CBDCA) in humans].
    Zucca E; Cattaneo MT; Cavalli F; Guaitani A; Filipazzi V; Bartosek I
    G Ital Chemioter; 1985; 32(1):25-8. PubMed ID: 3913618
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacokinetics and plasma protein binding of two platinum cytostatics CHIP and CBDCA in rats.
    Láznícková A; Láznícek M; Kvĕtina J; Drobník J
    Cancer Chemother Pharmacol; 1986; 17(2):133-6. PubMed ID: 3521926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo distribution studies of radioactively labelled platinum complexes; cis-dichlorodiammine platinum(II), cis-trans-dichlorodihydroxy-bis-(isopropylamine) platinum(IV), cis-dichloro-bis-cyclopropylamine platinum(II), and cis-diammine 1,1-cyclobutanedicarboxylate platinum(II) in patients with malignant disease, using a gamma camera.
    Owens SE; Thatcher N; Sharma H; Adam N; Harrison R; Smith A; Zaki A; Baer JC; McAuliffe CA; Crowther D
    Cancer Chemother Pharmacol; 1985; 14(3):253-7. PubMed ID: 3888431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II.
    Calvert AH; Harland SJ; Newell DR; Siddik ZH; Jones AC; McElwain TJ; Raju S; Wiltshaw E; Smith IE; Baker JM; Peckham MJ; Harrap KR
    Cancer Chemother Pharmacol; 1982; 9(3):140-7. PubMed ID: 6761010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats.
    Siddik ZH; Newell DR; Boxall FE; Harrap KR
    Biochem Pharmacol; 1987 Jun; 36(12):1925-32. PubMed ID: 3297068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell survival in four ovarian carcinoma xenografts following in vitro exposure to melphalan, cisplatin and cis-diammine-1,1-cyclobutane dicarboxylate platinum II (CBDCA,JM8).
    Jones AC; Wilson PA; Steel GG
    Cancer Chemother Pharmacol; 1984; 13(2):109-13. PubMed ID: 6380788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparation and characterization of platinum(II) and (IV) complexes of 1,3-diaminepropane and 1,4-diaminebutane: circumvention of cisplatin resistance and DNA interstrand cross-link formation in CH1cisR ovarian tumor cells.
    Alvarez-Valdés A; Pérez JM; López-Solera I; Lannegrand R; Continente JM; Amo-Ochoa P; Camazón MJ; Solans X; Font-Bardía M; Navarro-Ranninger C
    J Med Chem; 2002 Apr; 45(9):1835-44. PubMed ID: 11960495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Study on nephrotoxicity in rats receiving cis-diammine-1,1-cyclobutane dicarboxylate platinum II--special reference to morphological changes].
    Kimura S; Nakajima Y; Hasegawa S; Tazaki H
    Nihon Hinyokika Gakkai Zasshi; 1989 Apr; 80(4):517-25. PubMed ID: 2664296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of intestinal toxic effects of platinum complexes: cisplatin (CDDP), carboplatin (CBDCA), and iproplatin (CHIP).
    Kralovánszky J; Prajda N; Kerpel-Fronius S; Gál F; Kiss F
    Cancer Chemother Pharmacol; 1988; 21(1):40-4. PubMed ID: 3277733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I trial of cis-diammine-1,1-cyclobutane dicarboxylate platinum II (Carboplatin, CBDCA, JM-8) with a single dose every five week-schedule.
    Joss RA; Kaplan S; Goldhirsch A; Sessa C; Brunner KW; Cavalli F
    Invest New Drugs; 1984; 2(3):297-304. PubMed ID: 6392147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative distribution and excretion of carboplatin and cisplatin in mice.
    Siddik ZH; Jones M; Boxall FE; Harrap KR
    Cancer Chemother Pharmacol; 1988; 21(1):19-24. PubMed ID: 3277732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood clearance of three radioactively labelled platinum complexes: cis-dichlorodiammine platinum II, cis, trans-dichlorodihydroxy-bis-(isopropylamine) platinum IV, and cis-dichloro-bis-cyclopropylamine platinum II, in patients with malignant disease.
    Thatcher N; Sharma H; Harrison R; Smith A; Zaki A; McAuliffe CA; Crowther D; Fox BW
    Cancer Chemother Pharmacol; 1982; 9(1):13-6. PubMed ID: 6890414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of oxoplatinum and CBDCA on renal functions in rats.
    Láznícková A; Semecký V; Láznícek M; Zubr V; Koksál J; Kvĕtina J
    Neoplasma; 1989; 36(2):161-9. PubMed ID: 2654665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro stability, plasma protein binding and blood cell partitioning of 14C-carboplatin.
    Gaver RC; George AM; Deeb G
    Cancer Chemother Pharmacol; 1987; 20(4):271-6. PubMed ID: 3319277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ototoxicity of cisplatin vs. platinum analogs CBDCA (JM-8) and CHIP (JM-9).
    Schweitzer VG; Rarey KE; Dolan DF; Abrams G; Litterst CJ; Sheridan C
    Otolaryngol Head Neck Surg; 1986 Apr; 94(4):458-70. PubMed ID: 3086808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function.
    Egorin MJ; Van Echo DA; Tipping SJ; Olman EA; Whitacre MY; Thompson BW; Aisner J
    Cancer Res; 1984 Nov; 44(11):5432-8. PubMed ID: 6386150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental studies on the pharmacokinetics and nephrotoxicity of carboplatin (cis-diammine-1, 1-cyclobutane dicarboxylate platinum II) in rats.
    Ueda T; Yasumasu T; Uozumi J
    J Toxicol Sci; 1991 Aug; 16(3):101-9. PubMed ID: 1942134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of cis-diammine-1,1-cyclobutane dicarboxylatoplatinum(II)-induced DNA interstand cross-link removal and potentiation of cis-diammine-1,1-cyclobutane dicarboxylatoplatinum(II) cytotoxicity by hydroxyurea and 1-beta-D-arabinofuranosylcytosine.
    Swinnen LJ; Ellis NK; Erickson LC
    Cancer Res; 1991 Apr; 51(8):1984-9. PubMed ID: 2009517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 220.